Info

Running Through Walls

Running Through Walls is a Venrock podcast featuring candid conversations between investors and entrepreneurs. Each episode, we offer a behind-the-scenes look at the breakthroughs, challenges and nuttiness associated with building and growing companies. Venture capital firm Venrock has been investing in entrepreneurs across technology and healthcare since 1969.
RSS Feed
Running Through Walls
2024
January


2023
December
November
October
September
June
May
March
January


2022
December
November
October
September
August
May
March
February
January


2021
December
October
August
June
May
April
March
February
January


2020
December
November
October
September
August
June
February
January


2019
December
November
August
May
April
January


2018
October
September
June
May
April
March
February
January


2017
December
November
October
July
June
May
April
March
February
January


2016
December
November
October
September
August
July
June
May


All Episodes
Archives
Now displaying: October, 2020
Oct 28, 2020

Jennifer Bisceglie, CEO and founder of Interos, joins Venrock partner Nick Beim to discuss how Interos mitigates the challenges of third party risk management, particularly during the pandemic, by providing customers full visibility of their extended supply chain. Bisceglie describes how Interos continuously builds “family trees” of companies and scans for risk factors so customers can gain visibility into their supply chains and understand the vulnerabilities that can interrupt operations. She shares her proudest moments at Interos so far, the biggest challenge that female entrepreneurs face, and provides advice to women who are looking to start a business.

Oct 14, 2020

Venrock partner Camille Samuels speaks with Corvidia co-founders Ram Aiyar and Michael Davidson about Corvidia’s recent acquisition by Novo Nordisk, just four years after its founding. They discuss how inflammation contributes to cardiovascular disease – the number one killer in the United States – and how their drug Ziltivekimab “Zilti” is proving to be a successful therapy. Aiyar and Davidson share their experiences and advice for other companies exploring a sale, including always being ready for Plan B (or C), maintaining positive relationships, and not rushing any deals. They also discuss why the cardiovascular space is becoming increasingly appealing to entrepreneurs and investors when it was previously avoided. 

1